Product
KAZ954
1 clinical trial
1 indication
Indication
Solid TumorsClinical trial
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-09-15